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Cinnamon (肉桂 rou guì) has in vitro insulin potentiating activity, and proanthocyanidins from cinnamon
prevent in vitro formation of advanced glycation end products. Some human studies were equivocal, but
several have shown beneﬁcial effects of cinnamon supplementation on circulating glucose, lipids, and/or
insulin. This placebo-controlled double-blind trial tested the effects of a dried water extract of cinnamon
(Cinnamomum cassia) on circulating glucose, lipids, insulin, and insulin resistance. Men and women from
Beijing and Dalian, China, were invited to participate if they had fasting serum glucose >6.1 mmol/L or 2-
h glucose >7.8 mmol/L. Participants, (173 were enrolled and 137 completed the study) were randomly
assigned to receive either a spray-dried, water extract of cinnamon (CinSulin®), 250 mg/capsule, or a
placebo, twice a day for two months. Mean ± SEM age of participants was 61.3 ± 0.8 years, BMI was
25.3 ± 0.3 and M/F ratio was 65/72. After 2 mo, fasting glucose decreased (p < 0.001) in the cinnamon
extract-supplemented group (8.85 ± 0.36 to 8.19 ± 0.29 mmol/L) compared with the placebo group
(8.57 ± 0.32 to 8.44 ± 0.34 mmol/L, p ¼ 0.45). Glucose 2 h after a 75 g carbohydrate load, fasting insulin,
and HOMA-IR also decreased with cinnamon extract compared with placebo. Total and LDL-cholesterol
decreased with cinnamon extract and HDL-cholesterol decreased in both the cinnamon-extract and
placebo groups. In conclusion, supplementation with 500 mg of water-extract of cinnamon for two
months reduced fasting insulin, glucose, total cholesterol, and LDL cholesterol and enhanced insulin
sensitivity of subjects with elevated blood glucose.
Copyright © 2015, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cinnamon (Cinnamomum verum, Cinnamomum zeylanicum;錫蘭
肉桂 xı lan rou guì) and cassia (Cinnamomum aromaticum;中國肉桂
zhong guo rou guì) have a long history of uses as ﬂavoring agents,
preservatives, and pharmacological agents.1 In addition, in 2004,(R.A. Anderson).
for Food and Biomolecules,
molecules, National Taiwan Unive
ons.org/licenses/by-nc-nd/4.0/).Khan et al2 reported that subjects with type 2 diabetes given 1, 3 or
6 g of ground cinnamon per day for 40 days showed signiﬁcant
reductions in fasting serum glucose (18e29%), triglycerides
(23e30%), LDL cholesterol (7e27%), and total cholesterol (12e26%)
with no signiﬁcant changes in the placebo group. Several follow-up
human studies have also reported beneﬁcial effects of cinnamon on
people with varying degrees of glucose intolerance ranging from
normal to type 2 diabetes.313 Not all studies have reported bene-
ﬁcial effects of cinnamon or cinnamon extracts in human supple-
mentation trials. However, three of four recent meta-analyses
conclude that there are positive effects of supplemental cinnamon
or cinnamon extract and that further studies are needed.10,1416rsity. Production and hosting by Elsevier Taiwan LLC. This is an open access article
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a single positive study.13 The present study used a spray-dried
water-extract of cinnamon for supplementing adults with hyper-
glycemia in a placebo controlled double-blind two-month trial
conducted in China. In China, it is estimated that there are 90
million people with diabetes and over 150 million people with pre-
diabetes who are likely to become diabetic due to the current
rapidly changing lifestyle in China.17 (替代醫療 tì dai yı liao) are
urgently needed to control the hyperglycemia which precedes the
escalating incidence of type 2 diabetes and the resulting exploding
health care costs.
2. Research design and methods
2.1. Study participants
Men and women with fasting serum glucose >6.1 mmol/L or 2-
h glucose >7.8 mmol/L from the clinic of the General Hospital of
the 2nd Artillery, Beijing Tang-An Clinic and Dalian Dakang Clinic,
in Beijing and Dalian, China, were invited to join this study.
Exclusion factors were fasting glucose >20 mmol/L or 2-hr glucose
>25 mmol/L, serum insulin <5 IU, taking insulin therapy, or
serious complications such as cardiac/cerebral vascular diseases,
or renal dysfunction. The study was approved by the human use
committee of both hospitals and all participants gave informed
consent.18 Initially 173 persons were enrolled in the study, 89 in
the placebo group and 84 in the treatment group. A total of 137
completed the study with 73 in the placebo group and 64 in the
treatment group. No complications were reported in either the
placebo or the treatment groups; the 36 subjects who did not
complete the study were dropped because of a change in medi-
cation or missing a blood draw. Participants were asked to return
their capsule bottles to allow study personnel to conﬁrm study
compliance.
2.2. Study design
Study participants were assigned to groups using a random
number table in this double-blind placebo-controlled trial. The
treatment group received a commercially available spray-dried
water extract of cinnamon (肉桂 rou guì) (CinSulin®) containing
more than 4% type A procyanidin polyphenols,19 in 250 mg cap-
sules, twice a day. (This product does not contain added chromium
or Vitamin D which is found in some commercial products using
the same name). Type A procyanidin polyphenols are associated
with insulin potentiating,1922 antioxidant5,23 and anti-
inﬂammatory activities.24,25 The control group received placebo
capsules which contained 250 mg of dark brown (baked)
wheat ﬂour and were very similar in appearance to the cinnamon
extract.
2.3. Outcomes
In the present study, the by-group differences in fasting and in
2-hr serum glucose and in insulin resistance estimated as HOMA-IR
were the primary outcome variables. Additional measurements
included systolic and diastolic blood pressure, serum lipids, and
fructosamine.
2.4. Anthropometry and clinical procedures
Height and weight were measured initially and weight was
repeated at the end of the study. Subjects wore light clothing and
removed their shoes for thesemeasurements. Bodymass indexwas
calculated as weight (kg) divided by height (m2). The ChineseNutrition Society recommends BMI cutoffs of 28 for obesity and 24
for overweight.26
Blood pressure was measured after the participants had rested
for 15 min and measurements were repeated two times. Post-
prandial glucose was obtained by measuring plasma glucose two
hours after each participant consumed 100 g of white steamed
bread (equivalent to 75 g of carbohydrate).
2.5. Biochemical analyses
Serum glucose and lipids were analyzed on a Hitachi 7071A
clinical analyzer. Insulin was analyzed by radioimmunoassay and
fructosamine with a kit from RANDOX Laboratories.
2.6. Quantitative glycemic measures
The homeostasis model assessment for insulin resistance
(HOMA-IR) was used as a proxy measurement of insulin sensitivity.
HOMA-IR was calculated as (fasting serum glucose  fasting serum
insulin) divided by 22.5.27
2.7. Statistical analyses
Descriptive statistics were summarized as means and standard
error of themean using the SAS version 9.1 (SAS Institute, Cary, NC).
Parameters that were heavily right skewed (fasting insulin, HOMA-
IR, and triacylglycerols) were log transformed prior to statistical
analyses. Treatment effects were analyzed using analysis of vari-
ance with repeated measures (PROC MIXED) with an autore-
gressive period 1 error structure. The simple effect of treatment
given time (SLICE option in an LSMEANS statement) was used to
identify signiﬁcant changes from baseline with supplementation
with cinnamon extract.
3. Results
3.1. Baseline characteristics of subjects
Mean ± SEM age of participants was 61.3 ± 0.8 y; 47% were men.
Mean body mass index (BMI) was 25.3 ± 0.3 but 56% of the subjects
had BMI between 24e28, which based on Chinese standards,26 is
classiﬁed as overweight; nearly 14% were classiﬁed as obese with
BMI >28. Participants were hyperglycemic with baseline fasting
glucose values of 8.70 ± 0.24 mmol/L (Table 1). Baseline parameters
for the entire group for fasting insulin, postprandial glucose and
insulin, lipids and blood pressure are also shown in Table 1.
Fasting insulin and HOMA-IR were signiﬁcantly higher in the
overweight and obese groups than in the normal weight group
(Table 1). The insulin at 2 h after a glucose load was markedly and
signiﬁcantly higher in the obese group than in the groups with
lower BMIs. Glucose and fructosamine values were not different for
the three BMI groups. Diastolic blood pressure was signiﬁcantly
higher in the obese group. Total cholesterol and LDL-cholesterol
were not signiﬁcantly different by BMI, but HDL-cholesterol was
signiﬁcantly lower in the overweight and obese groups and tri-
acyglycerols were higher in those two groups.
At baseline, homeostasis model assessment-estimated that in-
sulin resistance (HOMA-IR) was signiﬁcantly correlated with dia-
stolic blood pressure (r ¼ 0.23) postprandial glucose (r ¼ 0.45),
insulin (r ¼ 0.42), triacylglycerols (r ¼ 0.29), fructosamine
(r ¼ 0.23), and BMI (r ¼ 0.29) and negatively correlated with HDL-
cholesterol (r ¼ 0.37).
Participants were assigned to placebo or treatment groups using
a random number table. There were no signiﬁcant differences at
baseline in any parameters between the two groups (Table 2). After
Table 1
Baseline characteristics of subjects and classiﬁcation by Chinese guidelines for body mass index (BMI) indicating normal, overweight, and obese.a
All BMI <24.0b BMI 24.0e<28.0c BMI 28.0d
Age, years 61.3 ± 0.8 59.0 ± 1.4 62.2 ± 1.0 62.4 ± 2.2
Fasting glucose, mmol/L 8.70 ± 0.24 8.99 ± 0.48 8.52 ± 0.28 8.82 ± 0.83
2-hr glucose, mmol/L 14.60 ± 0.42 14.61 ± 0.85 14.41 ± 0.51 15.37 ± 1.21
Fasting insulin, mU/L 22.9 ± 1.3 16.0 ± 1.3B 24.4 ± 1.8A 32.4 ± 4.2A
2-hr insulin, mU/L 89.4 ± 3.9 76.2 ± 6.9B 89.9 ± 5.0B 114.8 ± 9.8A
HOMA-IR 9.0 ± 0.6 6.6 ± 0.7B 9.4 ± 0.8A 13.2 ± 2.4A
Fructosamine, mmol/L 343 ± 6 338 ± 11 344 ± 8 350 ± 13
Systolic blood pressure, mm Hg 125.3 ± 1.2 122.9 ± 2.6 125.1 ± 1.5 131.4 ± 3.4
Diastolic blood pressure, mm Hg 77.0 ± 0.7 75.4 ± 1.4B 76.7 ± 0.8B 81.3 ± 2.2A
Total cholesterol, mmol/L 5.16 ± 0.09 5.19 ± 0.17 5.10 ± 0.11 5.35 ± 0.17
LDL cholesterol, mmol/L 3.46 ± 0.08 3.56 ± 0.15 3.38 ± 0.11 3.59 ± 0.20
HDL cholesterol, mmol/L 1.27 ± 0.03 1.41 ± 0.07A 1.23 ± 0.03B 1.16 ± 0.04B
Triacylglycerols, mmol/L 2.12 ± 0.13 1.54 ± 0.15B 2.32 ± 0.16A 2.54 ± 0.59A
a Mean ± SEM; Means (by BMI classiﬁcation) in a row with superscripts (uppercase alphabets) are signiﬁcantly different if they do not share a common letter. BMI clas-
siﬁcations are based on recommendations from the Chinese Diabetes Association.
b n ¼ 37e41 for glucose, insulin, HOMA-IR and blood pressure and 32 for lipids and fructosamine.
c n ¼ 77 for glucose, insulin, HOMA-IR and blood pressure and 63 for lipids and fructosamine.
d n ¼ 17e19 for glucose, insulin, HOMA-IR and blood pressure and 14e15 for lipids & fructosamine.
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cinnamon (肉桂 rou guì), the only signiﬁcant changes in the placebo
group were an increase in triacylglyerols (p < 0.0001), an increase
in systolic blood pressure (p < 0.05) and a decrease in HDL-
cholesterol (p < 0.005). Cinnamon extract supplementation, low-
ered fasting serum glucose (p < 0.001) in the cinnamon-
supplemented group, 8.85 ± 0.36 to 8.19 ± 0.29 mmol/L
(p < 0.005), comparedwith 8.57 ± 0.32 to 8.44 ± 0.34mmol/L in the
placebo control group (p ¼ 0.45). Serum glucose 2 h after a 75 g
carbohydrate load also decreased signiﬁcantly (p < 0.0001) in the
cinnamon extract-supplemented group, 15.09 ± 0.57 to
13.3 ± 0.55 mmol/L, compared with non-signiﬁcant differences in
the placebo group, 14.18 ± 0.60 to 13.74 ± 0.58 mmol/L. Fasting
insulin concentrations decreased signiﬁcantly and postprandial
insulin tended (p < 0.06) to be reduced by cinnamon extract sup-
plementation. Insulin sensitivity, assessed by HOMA-IR, was
signiﬁcantly improved by cinnamon extract as were fructosamine
concentrations.
Total cholesterol decreased with cinnamon extract supple-
mentation as did LDL-cholesterol. HDL-cholesterol was decreased
in both the placebo and cinnamon extract-supplemented groups
and triacylglycerols increased in both groups (Table 2). Responses
to cinnamon extract were independent of BMI.Table 2
Effects of placebo or supplementation with 250 mg water extract of cinnamon twice per
Placebo
n Baseline Fi
BMId 70 25.8 ± 0.3 2
Fasting glucose, mmol/L 73 8.57 ± 0.32 8
2-hr glucose, mmol/L 73 14.18 ± 0.60 13
Fasting insulin, mU/L 72 21.64 ± 1.66 23
2-hr insulin, mU/L 73 86.43 ± 5.19 82
HOMA-IR 72 8.51 ± 0.80 9
Fructosamine, mmol/L 57 348 ± 9
Systolic blood pressure, mmHg 72 122.7 ± 1.5 12
Diastolic blood pressure, mmHg 72 75.9 ± 0.9 7
Total cholesterol, mmol/L 57 5.12 ± 0.12 5
LDL cholesterol, mmol/L 57 3.45 ± 0.09 3
HDL cholesterol, mmol/L 57 1.28 ± 0.04 1
Triacylglycerols, mmol/L 57 2.05 ± 0.17 2
a Mean ± SEM.
b Placebo group e signiﬁcantly different from baseline ¤p < 0.05; ¤¤p < 0.005; ¤¤¤p <
c Cinnamon group e signiﬁcantly different from baseline *p < 0.05;**p < 0.005;***p <
d BMI ¼ Body Mass Index.4. Discussion
The incidence of type 2 diabetes (T2D) in China and worldwide
is exploding and the associated morbidity, mortality and costs have
energized the search for ways to reduce type 2 diabetes.28 Impaired
glucose tolerance (IGT) is a recognized intermediary condition be-
tween normal glucose regulation and T2DM and is associated with
a substantially elevated risk of disease progression.29 A recent
meta-analysis, looking at rates of natural progression to diabetes in
high-risk individuals, found that progression rates to diabetes in
subjects exhibiting elevated fasting glucose, IGT, or both are
roughly double those for normal glucose tolerance progressing to
diabetes.30,31 These results point to plasma glucose levels as a po-
tential target to reduce progression to and hence prevalence of type
2 diabetes. Studies of pharmaceutical agents such as metformin,32
acarbose,33 and pioglitazone,34 that all lower glucose levels, were
found to lower diabetes mellitus onset in high-risk populations.
However the high costs, side effects and difﬁcult compliance issues
of these interventions have slowed or blocked widespread
implementation.
Cinnamon (肉桂 rou guì) extract may offer a low cost, readily
available and relatively easily implemented means of reducing
plasma glucose levels and thereby reducing T2D. The present studyday for two months in hyperglycemic adults.a,b,c
Cinnamon (肉桂 rou guì)
nal n Baseline Final
5.6 ± 0.3 63 24.8 ± 0.4 24.6 ± 0.4
.44 ± 0.34 64 8.85 ± 0.36 8.19 ± 0.29**
.74 ± 0.58 64 15.09 ± 0.57 13.30 ± 0.55***
.65 ± 3.02 63 24.25 ± 2.01 22.26 ± 2.08*
.58 ± 4.84 59 93.13 ± 5.78 83.17 ± 4.53
.12 ± 1.32 63 9.67 ± 0.90 8.32 ± 0.84**
338 ± 8 51 336 ± 8 319 ± 7*
6.2 ± 1.8¤ 63 128.3 ± 1.9 131.1 ± 1.9
7.4 ± 1.0 63 78.2 ± 1.1 77.2 ± 1.1
.05 ± 0.14 53 5.20 ± 0.14 4.96 ± 0.16*
.35 ± 0.11 53 3.48 ± 0.14 3.25 ± 0.14**
.21 ± 0.04¤¤ 53 1.26 ± 0.04 1.17 ± 0.04**
.48 ± 0.19¤¤¤ 53 2.20 ± 0.21 2.58 ± 0.28*
0.0001.
0.0001.
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fully characterize the response of plasma glucose metabolism in
Chinese adults with hyperglycemia to daily consumption of a well-
deﬁned, spray-dried water-extract of cinnamon. Study participants
were hyperglycemic and 70% were overweight or obese based on
the Chinese standards for BMI.26 Recent research suggests that
adipose tissue is an active endocrine organ that releases cytokines
and contributes to inﬂammation and ultimately to insulin
resistance.3537 In our study, fasting insulinwas twice as high in the
groupwith BMI above 28 compared to the groupwith BMI less than
24. Likewise, insulin resistance estimated by HOMA-IR and tri-
acylglycerols were signiﬁcantly elevated in the overweight and
obese BMI groups and BMI was correlated with diastolic blood
pressure, fasting insulin and triacylglycerols.
Meeting the criteria for metabolic syndrome was not required
for participation in this study; thus, no measure of central obesity
was taken. However, many of the men and women had lipid and
blood pressure values consistent with metabolic syndrome in
addition to their elevated fasting glucose. Speciﬁcally, 40% of the
men andwomen had inappropriately lowHDL-cholesterol, 53% had
triglycerides above 1.7 mmol and 46% had systolic or diastolic blood
pressure above 130/85.38
Mechanisms by which cinnamon or cinnamon extract supple-
ments lower glucose, insulin and estimates of insulin resistance are
not yet completely clear, but food composition analyses, in vitro,
animal, and human studies suggest possibilities. Proanthocyani-
dins, which are high in cinnamon, are plant metabolites with
antioxidant activity.39 Cinnamon has a particularly high hydrophilic
oxygen radical absorbance capacity (ORAC)/total phenolics ratio.23
Furthermore, cinnamon bark extracts inhibited the formation
in vitro of advanced glycation end products (AGEs) which
contribute to diabetic complications. This inhibition has been
attributed to the ability of phenolic compounds in the extracts to
trap reactive carbonyl species.40 Antioxidant variables, ferric
reducing antioxidant potential and plasma thiols, increased while
plasma malondyaldehyde (MDA) levels decreased in subjects
receiving a cinnamon extract similar to the one used in this study.5
In tests of insulin activity using the rat epididymal fat cell assay,
cinnamon extracts produced the greatest enhancement of glucose
utilization of all the forty-nine herb, spice, and medicinal plant
extracts tested.20 Subsequently, water-soluble polyphenolic poly-
mers from cinnamon were found to increase insulin activity by
approximately twenty-fold in the same assay.19
Several steps in insulin signaling pathways are affected by cin-
namon extracts. Various cinnamon compounds effect protein
phosphorylation-dephosphorylation reactions in adipocytes.21,22
Another study suggested that a cinnamon extract affects a tyro-
sine phosphatase that would otherwise inactivate the insulin re-
ceptor21 and Cao and coworkers reported that a water extract of
cinnamon increased insulin-dependent glucose transporter 4
(GLUT4). Cheng et al41 reported that water soluble cinnamon
polyphenols inhibited glucose production that was accompanied
by decreased expression of phosphoenolpyruvate carboxykinase
and glucose-6-phosphatase, major regulators of hepatic gluco-
neogenesis. Inﬂammatory processes also contribute to insulin
resistance.36,37 The anti-inﬂammatory protein, tristetraprolin (TPP),
is increased by cinnamon extracts.24 TPP is reduced in obese people
with metabolic syndrome, but both TPP mRNA and protein levels
are increased by cinnamon.25 A cinnamon extract seems to have the
potential to increase proteins involved in insulin signaling, glucose
transport, and the anti-inﬂammatory responses and decreases
those involved in gluconeogenesis.
Beneﬁcial effects of cinnamon extract may also derive from in-
teractions with peroxisome proliferator-activated receptor gamma
(PPARg), a regulator of adipogenesis and insulin sensitivity.Considerable effort has been focused on drugs that would serve as
ligands for this receptor.42 Mueller and Jungbauer noted that cin-
namon extracts bound PPARg in competitive ligand binding as-
says.43 Kim and Choung suggest that cinnamon regulates insulin
sensitivity by regulating PPAR-mediated glucose metabolism.44
Qin et al45 reported a signiﬁcantly higher glucose utilization rate
in animals fed a cinnamon extract compared to the rate in control
rats. They suggested that cinnamon extract may improve insulin
action via increasing glucose uptake, perhaps through enhancing
the insulin-signaling pathway in skeletal muscle.
More investigation is needed of dietary factors involved in
control of glucose homeostasis. Insulin resistance seems to be a
common factor in virtually all markers for metabolic syndrome.
Obesity is associated with low-grade inﬂammation, but cinnamon
extract may have a role in reducing pro-inﬂammatory factors that
promote insulin resistance. Moreover, cinnamon and cinnamon
extract are rich sources of proanthocyanins that may be particularly
effective in quelling inﬂammatory compounds and stimulating in-
sulin signaling pathways.25,46
The unexpected increase in triacylglycerols is not consistent
with any of the previous studies and is likely due to unidentiﬁed
dietary changes since it was present in both the treatment and
placebo groups.
5. Conclusion
This study documents the beneﬁcial effects of 500 mg of a cin-
namon (肉桂 rou guì) extract per day on Chinese adults with
elevated blood glucose. The cinnamon extract used in this study
was a commercially available spray-dried water extract of cinna-
mon (CinSulin®) containing more than 4% of type A procyanidin
polyphenols which are associated with improvements in insulin
potentiating, antioxidant and anti-inﬂammatory activities. As
demonstrated by this and related studies, cinnamon extract should
be considered for the prevention and alleviation of elevated blood
glucose thereby likely reducing progression to type 2 diabetes and
its associated morbidity and mortality.
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